Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice

Bara-Jimenez, 2003, Adenosine A(2A) receptor antagonist treatment of Parkinson's disease, Neurology, 61, 293, 10.1212/01.WNL.0000073136.00548.D4 Calon, 2004, Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias, Brain, 127, 1075, 10.1093/brain/awh128 Chase, 2003, Translating A2A antagonist KW6002 from animal models to parkinsonian patients, Neurology, 61, S107, 10.1212/01.WNL.0000095223.08711.48 Chen, 2001, Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease, J. Neurosci., 21, RC143, 10.1523/JNEUROSCI.21-10-j0001.2001 Ekstrand, 2007, Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons, Proc. Natl Acad. Sci. USA, 104, 1325, 10.1073/pnas.0605208103 Fahn, 2005, Does levodopa slow or hasten the rate of progression of Parkinson's disease, J. Neurol., 252 Suppl 4, IV37 Fenu, 1997, Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats, Eur. J. Pharmacol., 321, 143, 10.1016/S0014-2999(96)00944-2 Fernandez, 2010, Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial, Parkinsonism Relat. Disord., 16, 16, 10.1016/j.parkreldis.2009.06.008 Ferre, 1991, Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes, Proc. Natl Acad. Sci. USA, 88, 7238, 10.1073/pnas.88.16.7238 Fredholm, 1976, Effect of some phosphodiesterase inhibitors on central dopamine mechanisms, Eur. J. Pharmacol., 38, 31, 10.1016/0014-2999(76)90198-9 Fuxe, 2003, Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease, Neurology, 61, S19, 10.1212/01.WNL.0000095206.44418.5C Fuxe, 2007, Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease, Mov. Disord., 22, 1990, 10.1002/mds.21440 Fuxe, 1974, Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists, Med. Biol., 52, 48 Galter, 2010, MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease, Genes Brain Behav., 9, 173, 10.1111/j.1601-183X.2009.00542.x Hauser, 2009, New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy, Parkinsonism Relat. Disord., 15, S17, 10.1016/S1353-8020(09)70772-2 Hauser, 2003, Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD, Neurology, 61, 297, 10.1212/01.WNL.0000081227.84197.0B Hockemeyer, 2004, Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease, J. Org. Chem., 69, 3308, 10.1021/jo0358574 Ikeda, 2002, Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease, J. Neurochem., 80, 262, 10.1046/j.0022-3042.2001.00694.x Jankovic, 2008, Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?, Ann. Neurol., 63, 267, 10.1002/ana.21348 Jenner, 2009, Adenosine, adenosine A 2A antagonists, and Parkinson's disease, Parkinsonism Relat. Disord., 15, 406, 10.1016/j.parkreldis.2008.12.006 Kanda, 1998, Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys, Ann. Neurol., 43, 507, 10.1002/ana.410430415 Karcz-Kubicha, 2003, Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration, Neuropsychopharmacology, 28, 1281, 10.1038/sj.npp.1300167 Nagel, 2003, Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats, Synapse, 49, 279, 10.1002/syn.10240 Ross, 2000, Association of coffee and caffeine intake with the risk of Parkinson disease, JAMA, 283, 2674, 10.1001/jama.283.20.2674 Sauer, 2000, Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists, J. Med. Chem., 43, 440, 10.1021/jm9911480 Schwarzschild, 2006, Targeting adenosine A2A receptors in Parkinson's disease, Trends Neurosci., 29, 647, 10.1016/j.tins.2006.09.004 Svenningsson, 1999, Distribution, biochemistry and function of striatal adenosine A2A receptors, Prog. Neurobiol., 59, 355, 10.1016/S0301-0082(99)00011-8 Tanganelli, 2004, Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease, Parkinsonism Relat. Disord., 10, 273, 10.1016/j.parkreldis.2004.02.015 Yang, 2007, Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists, Naunyn. Schmiedebergs Arch. Pharmacol., 375, 133, 10.1007/s00210-007-0135-0